Literature DB >> 22841966

Reduced antioxidant defense systems in schizophrenia and bipolar I disorder.

Monia Raffa1, Sana Barhoumi, Fatma Atig, Chiraz Fendri, Abdelhamid Kerkeni, Anwar Mechri.   

Abstract

Numerous evidence and proofs suggest that the oxidative stress contributes to the pathogenesis of schizophrenia (SZ) and bipolar disorder (BD). The aim of this study is to determine the glutathione levels and the antioxidant enzyme activities in blood samples of patients suffering from SZ and patients with bipolar disorder in comparison with the healthy controlled subjects. It was a case-controlled study carried on upon three groups: forty-six SZ patients (41 men and 5 women, mean age=33.2±7years), thirty BD patients (25 men and 5 women, mean age=31.3±8years) and forty healthy controls (33 men and 7 women, mean age=32.3±7years). The glutathione levels are the total glutathione (GSHt), the reduced glutathione (GSHr), and the oxidized glutathione (GSSG) and the antioxidant enzyme activities that are the superoxide dismutase (SOD), the glutathione peroxidase (GPx), and the catalase (CAT) are determined by the spectrophotometer. We noticed that the GSHt and the GSHr levels significantly decreased in both SZ and BD patients in comparison with the healthy control subjects. As for SOD and CAT activities they remained lower for the patients with SZ when compared both with the controls or the BD patients. We noticed as well that the CAT activity was significantly lower in the BD group than that in the control group, whereas, GPx activity showed no significant change in each group. Hence, this report of the decreased plasma levels of GSHt and GSHr, and the impaired antioxidant enzyme activities in SZ and BD patients aims at highlighting the GSH deficit that seems to be contributing to these disorders, and showing that it may be an important indirect biomarker of the oxidative stress for the SZ and BD.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22841966     DOI: 10.1016/j.pnpbp.2012.07.013

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  28 in total

1.  Oxidative stress in early stage Bipolar Disorder and the association with response to lithium.

Authors:  Rafael T de Sousa; Carlos A Zarate; Marcus V Zanetti; Alana C Costa; Leda L Talib; Wagner F Gattaz; Rodrigo Machado-Vieira
Journal:  J Psychiatr Res       Date:  2013-12-06       Impact factor: 4.791

2.  GBR 12909 administration as an animal model of bipolar mania: time course of behavioral, brain oxidative alterations and effect of mood stabilizing drugs.

Authors:  Ana Isabelle G Queiroz; Maíra Moraes de Araújo; Tatiane da Silva Araújo; Greicy Coelho de Souza; Lígia Menezes Cavalcante; Michel de Jesus Souza Machado; David Freitas de Lucena; João Quevedo; Danielle Macêdo
Journal:  Metab Brain Dis       Date:  2015-06-16       Impact factor: 3.584

3.  Evaluation of Oxidative Stress in Bipolar Disorder in terms of Total Oxidant Status, Total Antioxidant Status, and Oxidative Stress Index.

Authors:  Merve Cingi Yirün; Kübranur Ünal; Neslihan Altunsoy Şen; Onur Yirün; Çiğdem Aydemir; Erol Göka
Journal:  Noro Psikiyatr Ars       Date:  2016-09-01       Impact factor: 1.339

Review 4.  Targeting mitochondrially mediated plasticity to develop improved therapeutics for bipolar disorder.

Authors:  Rafael T de Sousa; Rodrigo Machado-Vieira; Carlos A Zarate; Husseini K Manji
Journal:  Expert Opin Ther Targets       Date:  2014-07-24       Impact factor: 6.902

Review 5.  A Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical Correlates.

Authors:  Sarel J Brand; Marisa Moller; Brian H Harvey
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

Review 6.  Antioxidants as potential therapeutics for neuropsychiatric disorders.

Authors:  Chirayu D Pandya; Kristy R Howell; Anilkumar Pillai
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-11-02       Impact factor: 5.067

7.  Serum Oxidative Stress Marker Levels in Unmedicated and Medicated Patients with Schizophrenia.

Authors:  Zhi-Le Bai; Xue-Song Li; Guang-Yang Chen; Yang Du; Ze-Xu Wei; Xi Chen; Guang-En Zheng; Wen Deng; Yong Cheng
Journal:  J Mol Neurosci       Date:  2018-10-09       Impact factor: 3.444

8.  Cortical glutathione levels in young people with bipolar disorder: a pilot study using magnetic resonance spectroscopy.

Authors:  Beata R Godlewska; Sarah W Yip; Jamie Near; Guy M Goodwin; Philip J Cowen
Journal:  Psychopharmacology (Berl)       Date:  2013-08-17       Impact factor: 4.530

9.  Matrix Metalloproteinase 9 Blood Alterations in Patients With Schizophrenia Spectrum Disorders: A Systematic Review and Meta-Analysis.

Authors:  Georgios Schoretsanitis; Renato de Filippis; Maria Ntogka; Stefan Leucht; Christoph U Correll; John M Kane
Journal:  Schizophr Bull       Date:  2021-07-08       Impact factor: 9.306

10.  A multimodal approach to studying the relationship between peripheral glutathione, brain glutamate, and cognition in health and in schizophrenia.

Authors:  Kun Yang; Anouk Marsman; Subechhya Pradhan; Jennifer M Coughlin; Min Wang; Rebecca E Ward; Susanne Bonekamp; Emily B Ambinder; Cecilia P Higgs; Pearl K Kim; Jamie A Edwards; Mark Varvaris; Hongxing Wang; Sotirios Posporelis; Shuangchao Ma; Tsuyoshi Tsujimura; Richard A E Edden; Martin G Pomper; Thomas W Sedlak; Margot Fournier; David J Schretlen; Nicola G Cascella; Peter B Barker; Akira Sawa
Journal:  Mol Psychiatry       Date:  2020-10-19       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.